» Articles » PMID: 23238889

Differential Effects of Exogenous and Autocrine Growth Hormone on LNCaP Prostate Cancer Cell Proliferation and Survival

Overview
Journal J Cell Biochem
Date 2012 Dec 15
PMID 23238889
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The prostate gland is regulated by multiple hormones and growth factors that may also affect prostate tumorigenesis. Growth hormone (GH) contributes to prostate development and function, but the direct effects of GH on prostate cancer cells are not well understood. The expression of endogenous GH in prostate cancer cell lines has also been observed, suggesting the potential for an effect of autocrine GH. In the present study, we measure the levels of GH and GH receptor (GHR) mRNA in multiple prostate cancer and normal prostate-derived cell lines, and compare the effects of exogenous and autocrine GH on LNCaP prostate cancer cell proliferation and apoptosis, and the associated signal transduction pathways. We found that GHR and GH expression were higher in the prostate cancer cell lines, and that exogenous GH increased LNCaP cell proliferation, but had no effect on apoptosis. In contrast, autocrine GH overexpression reduced LNCaP cell proliferation and increased apoptosis. The distinct actions of exogenous and autocrine GH were accompanied by differences in the involvement of GHR-associated signal transduction pathways, and were paralleled by an alteration in the subcellular localization of GHR, in which autocrine GH appeared to sequester GHR in the Golgi and endoplasmic reticulum. This alteration of GHR trafficking may underlie a distinct mode of GH-mediated signaling associated with the effect of autocrine GH. These findings clarify the potential effects of GH on prostate cancer cell function, and indicate that the activity of autocrine GH may be distinct from that of endocrine GH in prostate cancer cells.

Citing Articles

Stat5 induces androgen receptor () gene transcription in prostate cancer and offers a druggable pathway to target AR signaling.

Maranto C, Sabharwal L, Udhane V, Pitzen S, McCluskey B, Qi S Sci Adv. 2024; 10(9):eadi2742.

PMID: 38416822 PMC: 10901378. DOI: 10.1126/sciadv.adi2742.


WIP1 is a novel specific target for growth hormone action.

Apaydin T, Zonis S, Zhou C, Valencia C, Barrett R, Strous G iScience. 2023; 26(11):108117.

PMID: 37876819 PMC: 10590974. DOI: 10.1016/j.isci.2023.108117.


Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas.

Voltan G, Mazzeo P, Regazzo D, Scaroni C, Ceccato F Int J Mol Sci. 2023; 24(12).

PMID: 37373068 PMC: 10297914. DOI: 10.3390/ijms24129920.


Exogenous growth hormone promotes an epithelial-mesenchymal hybrid phenotype in cancerous HeLa cells but not in non-cancerous HEK293 cells.

Olascoaga-Caso E, Tamariz-Dominguez E, Rodriguez-Alba J, Juarez-Aguilar E Mol Cell Biochem. 2022; 478(5):1117-1128.

PMID: 36222986 DOI: 10.1007/s11010-022-04583-1.


GH Action in Prostate Cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates Cancer-related Gene Expression.

Unterberger C, Maklakova V, Lazar M, Arneson P, Mcilwain S, Tsourkas P Endocrinology. 2022; 163(5).

PMID: 35383352 PMC: 8995093. DOI: 10.1210/endocr/bqac031.